The risks of prescribing GLP-1 drugs: Pharma ties and kickbacks

The risks of prescribing GLP-1 drugs: Pharma ties and kickbacks

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

Patients Cut Off From Cheaper Obesity Drugs as the F.D.A. Halts Sales of Copycats

(New York Times) – U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound. (Read More)

The GLP-1 drug shortage is over. What’s next for the compounders? - Pharmaceutical Technology

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.